PRA Health Sciences (PRAH) Tops Q4 EPS by 1c

PRA Health Sciences (NASDAQ: PRAH) reported Q4 EPS of $1.04, $0.01 better than the analyst estimate of $1.03. Revenue for the quarter came in at $568.8 million versus the consensus estimate of $543.54 million.

GUIDANCE:

PRA Health Sciences sees FY2018 EPS of $4.00-$4.15, versus the consensus of $4.06. PRA Health Sciences sees FY2018 revenue of $2.84-2.95 billion.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'
• Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch